Aimmune Therapeutics Inc. (AIMT) and Krystal Biotech Inc. (NASDAQ:KRYS) Contrasting side by side

Both Aimmune Therapeutics Inc. (NASDAQ:AIMT) and Krystal Biotech Inc. (NASDAQ:KRYS) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aimmune Therapeutics Inc. 21 -0.15 36.95M -3.62 0.00
Krystal Biotech Inc. 44 0.00 8.65M -1.04 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 represents Aimmune Therapeutics Inc. (NASDAQ:AIMT) and Krystal Biotech Inc. (NASDAQ:KRYS)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Aimmune Therapeutics Inc. 172,744,273.02% -79.1% -66.4%
Krystal Biotech Inc. 19,798,580.91% -16% -15.5%


The current Quick Ratio of Aimmune Therapeutics Inc. is 7.6 while its Current Ratio is 7.6. Meanwhile, Krystal Biotech Inc. has a Current Ratio of 33.3 while its Quick Ratio is 33.3. Krystal Biotech Inc. is better positioned to pay off its short-term and long-term debts than Aimmune Therapeutics Inc.

Analyst Ratings

The table shown features the ratings and recommendations for Aimmune Therapeutics Inc. and Krystal Biotech Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aimmune Therapeutics Inc. 0 1 0 2.00
Krystal Biotech Inc. 0 1 1 2.50

Aimmune Therapeutics Inc. has a 58.12% upside potential and an average target price of $33. On the other hand, Krystal Biotech Inc.’s potential upside is 57.26% and its average target price is $55.67. Based on the data shown earlier, Aimmune Therapeutics Inc. is looking more favorable than Krystal Biotech Inc., analysts belief.

Insider and Institutional Ownership

Institutional investors held 86.3% of Aimmune Therapeutics Inc. shares and 39.1% of Krystal Biotech Inc. shares. Insiders held roughly 0.6% of Aimmune Therapeutics Inc.’s shares. Insiders Comparatively, held 32.99% of Krystal Biotech Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aimmune Therapeutics Inc. 1.91% -9.03% -2.92% -15.79% -29.77% -19.52%
Krystal Biotech Inc. -0.48% 8.11% 48.27% 110.06% 207.26% 131.04%

For the past year Aimmune Therapeutics Inc. has -19.52% weaker performance while Krystal Biotech Inc. has 131.04% stronger performance.


Krystal Biotech Inc. beats on 8 of the 12 factors Aimmune Therapeutics Inc.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.

Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases. The companyÂ’s lead product candidate includes KB103, which is in preclinical studies to treat dystrophic epidermolysis bullosa, a genetic disease. It also develops KB104 that is in preclinical studies to treat Netherton syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is based in Pittsburgh, Pennsylvania.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.